These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. DeVita VT Cancer; 1983 Apr; 51(7):1209-20. PubMed ID: 6825044 [TBL] [Abstract][Full Text] [Related]
4. Cancer chemotherapy. Secchi GC Ann Ital Med Int; 1990; 5(3 Pt 3):288-95. PubMed ID: 2081089 [TBL] [Abstract][Full Text] [Related]
5. Cancer Drug Development: New Targets for Cancer Treatment. Curt GA Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987 [TBL] [Abstract][Full Text] [Related]
6. Advances in the management of epithelial ovarian cancer. Berkenblit A; Cannistra SA J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567 [TBL] [Abstract][Full Text] [Related]
8. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
9. The Goal of Cancer Treatment. Balis FM Oncologist; 1998; 3(4):V. PubMed ID: 10388118 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753 [TBL] [Abstract][Full Text] [Related]
11. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Andrews P; Zhao X; Allen J; Li F; Chang M Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067 [TBL] [Abstract][Full Text] [Related]
12. The Challenge of Developing New Therapies for Childhood Cancers. Balis FM Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032 [TBL] [Abstract][Full Text] [Related]
13. The rationale for the use of preoperative chemotherapy. Goldie JH Prog Clin Biol Res; 1985; 201():5-14. PubMed ID: 3912767 [TBL] [Abstract][Full Text] [Related]
14. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
16. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Coldman AJ; Goldie JH Semin Oncol; 1987 Dec; 14(4 Suppl 4):29-33. PubMed ID: 3686044 [TBL] [Abstract][Full Text] [Related]
17. [Kinetics of breast neoplasms]. Surbone A; Norton L Minerva Med; 1994; 85(1-2):7-16. PubMed ID: 8152580 [TBL] [Abstract][Full Text] [Related]
18. Curative and palliative aspects of regional chemotherapy in combination with surgery. Müller H; Hilger R Support Care Cancer; 2003 Jan; 11(1):1-10. PubMed ID: 12527948 [TBL] [Abstract][Full Text] [Related]
19. Establishment of in-vitro models of chemotherapy resistance. Watson MB; Lind MJ; Cawkwell L Anticancer Drugs; 2007 Aug; 18(7):749-54. PubMed ID: 17581296 [TBL] [Abstract][Full Text] [Related]
20. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]